Monique Gilbert
Physician Assistant · Melbourne, FLNPI 1154729606
Payments from drug & device makers
Across 218 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$496
- Novo Nordisk$423
- Novartis$346
- AbbVie$313
- Boehringer Ingelheim$311
- Lilly USA, LLC$295
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,894100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $496 |
| Novo Nordisk | 31 | $423 |
| Novartis | 32 | $346 |
| AbbVie | 16 | $313 |
| Boehringer Ingelheim | 17 | $311 |
| Lilly USA, LLC | 15 | $295 |
| Amgen | 15 | $287 |
| Phathom Pharmaceuticals, Inc. | 3 | $229 |
| Bayer | 9 | $190 |
| Esperion Therapeutics, Inc. | 8 | $152 |
| Pfizer | 8 | $149 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $124 |
| Abbott | 5 | $107 |
| Daiichi Sankyo Inc. | 5 | $90 |
| Merck | 4 | $69 |
| GSK | 3 | $54 |
| Amarin Pharma, Inc. | 3 | $44 |
| Eisai Inc. | 1 | $32 |
| Boston Scientific | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Medtronic | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Alvogen Inc | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$3,894 in reported general payments places this provider in the 85th percentile of 8,062 physician assistant providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $69,503 |
| MounjaroTirzepatide | 27 | $27,685 |
| OzempicSemaglutide | 25 | $27,456 |
| Rosuvastatin Calcium | 281 | $4,846 |
| Valsartan | 116 | $4,096 |
| Ezetimibe | 95 | $2,849 |
| Metoprolol Succinate | 91 | $1,751 |
| Nebivolol Hcl | 19 | $1,489 |
| Omeprazole | 55 | $1,249 |
| Levothyroxine Sodium | 73 | $1,096 |
| Pantoprazole Sodium | 81 | $1,080 |
| Losartan Potassium | 64 | $975 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 29 | $850 |
| Amlodipine Besylate | 79 | $816 |
| Atorvastatin Calcium | 66 | $750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $311 | $69,50358 claims |
| Lilly USA, LLCMounjaro | $295 | $27,68527 claims |
| Novo NordiskOzempic | $423 | $27,45625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Melbourne
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
- Ashley MillerGainesville$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.